Yousef Al-Abed

List of Publications by Year
in descending order

165 papers	14,803 citations	38742 50 h-index	19190 118 g-index
177 all docs	177 docs citations	177 times ranked	15357 citing authors

#	Article	IF	Citations
1	A fully implantable wireless bidirectional neuromodulation system for mice. Biosensors and Bioelectronics, 2022, 200, 113886.	10.1	21
2	Azapeptides -A History of Synthetic Milestones and Key Examples. Current Medicinal Chemistry, 2022, 29, .	2.4	4
3	Development and characterization of a chronic implant mouse model for vagus nerve stimulation. ELife, 2021, 10, .	6.0	28
4	The Fourth Bioelectronic Medicine Summit â€œTechnology Targeting Molecular Mechanismsâ€: current progress, challenges, and charting the future. Bioelectronic Medicine, 2021, 7, 7.	2.3	5
5	Redox modifications of cysteine residues regulate the cytokine activity of HMGB1. Molecular Medicine, 2021, 27, 58.	4.4	25
6	Implant- and anesthesia-related factors affecting cardiopulmonary threshold intensities for vagus nerve stimulation. Journal of Neural Engineering, 2021, 18, 046075.	3.5	18
7	A Nonlethal Murine Flame Burn Model Leads to a Transient Reduction in Host Defenses and Enhanced Susceptibility to Lethal Pseudomonas aeruginosa Infection. Infection and Immunity, 2021, 89, e0009121.	2.2	4
8	Human Dermcidin Protects Mice Against Hepatic Ischemia-Reperfusionâ€“Induced Local and Remote Inflammatory Injury. Frontiers in Immunology, 2021, 12, 821154.	4.8	4
9	Î²2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development. Science Translational Medicine, 2021, 13, eabk2267.	12.4	23
10	Extracellular micro<scp>RNA</scp> 130bâ€3p inhibits <scp>eCIRP</scp>â€induced inflammation. EMBO Reports, 2020, 21, e48075.	4.5	40
11	Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics. Future Medicinal Chemistry, 2020, 12, 1647-1656.	2.3	49
12	Let Sleeping Patients Lie, avoiding unnecessary overnight vitals monitoring using a clinically based deep-learning model. Npj Digital Medicine, 2020, 3, 149.	10.9	10
13	Quantitative estimation of nerve fiber engagement by vagus nerve stimulation using physiological markers. Brain Stimulation, 2020, 13, 1617-1630.	1.6	52
14	Anodal block permits directional vagus nerve stimulation. Scientific Reports, 2020, 10, 9221.	3.3	34
15	Expression of Concern to: Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Molecular Medicine, 2020, 26, 18.	4.4	3
16	Key role of MIF-related neuroinflammation in neurodegeneration and cognitive impairment in Alzheimerâ€™s disease. Molecular Medicine, 2020, 26, 34.	4.4	46
17	Inhibition of IRF5 hyperactivation protects from lupus onset and severity. Journal of Clinical Investigation, 2020, 130, 6700-6717.	8.2	48
18	Correcting Smad1/5/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models. Journal of Clinical Investigation, 2020, 130, 942-957.	8.2	48

#	Article	IF	Citations
19	Large-Scale Validation of the Paddling Pool Task in the Clockmaze for Studying Hippocampus-Based Spatial Cognition in Mice. Frontiers in Behavioral Neuroscience, 2019, 13, 121.	2.0	5
20	Senescence as a main mechanism of Ritonavir and Ritonavirâ€NO action against melanoma. Molecular Carcinogenesis, 2019, 58, 1362-1375.	2.7	18
21	Forebrain Cholinergic Signaling Regulates Innate Immune Responses and Inflammation. Frontiers in Immunology, 2019, 10, 585.	4.8	55
22	Inhibition of HMGB1/RAGE-mediated endocytosis by HMGB1 antagonist box A, anti-HMGB1 antibodies, and cholinergic agonists suppresses inflammation. Molecular Medicine, 2019, 25, 13.	4.4	75
23	Therapeutic Targeting of High-Mobility Group Box-1 in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1566-1569.	5.6	21
24	Rediscovering MIF: New Tricks for an Old Cytokine. Trends in Immunology, 2019, 40, 447-462.	6.8	59
25	Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo. Investigational New Drugs, 2019, 37, 1014-1028.	2.6	41
26	Pulmonary arterial hypertension: the case for a bioelectronic treatment. Bioelectronic Medicine, 2019, 5, 20.	2.3	15
27	Endogenous retroviruses are associated with hippocampus-based memory impairment. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25982-25990.	7.1	39
28	Mechanistic insights into high mobility group box-1 (HMGb1)-induced Toll-like receptor 4 (TLR4) dimer formation. Journal of Biomolecular Structure and Dynamics, 2019, 37, 3721-3730.	3.5	17
29	High Mobility Group Box-1 (HMGb1): Current Wisdom and Advancement as a Potential Drug Target. Journal of Medicinal Chemistry, 2018, 61, 5093-5107.	6.4	90
30	Connexin 43 Hemichannel as a Novel Mediator of Sterile and Infectious Inflammatory Diseases. Scientific Reports, 2018, 8, 166.	3.3	50
31	High mobility group box 1 orchestrates tissue regeneration via CXCR4. Journal of Experimental Medicine, 2018, 215, 303-318.	8.5	131
32	Adenylyl Cyclase 6 Mediates Inhibition of TNF in the Inflammatory Reflex. Frontiers in Immunology, 2018, 9, 2648.	4.8	49
33	Folic acid derived-P5779 mimetics regulate DAMP-mediated inflammation through disruption of HMGB1:TLR4:MD-2 axes. PLoS ONE, 2018, 13, e0193028.	2.5	15
34	DNA-Mediated Interferon Signature Induction by SLE Serum Occurs in Monocytes Through Two Pathways: A Mechanism to Inhibit Both Pathways. Frontiers in Immunology, 2018, 9, 2824.	4.8	32
35	Anticancer and Differentiation Properties of the Nitric Oxide Derivative of Lopinavir in Human Glioblastoma Cells. Molecules, 2018, 23, 2463.	3.8	36
36	Contribution of the macrophage migration inhibitory factor superfamily of cytokines in the pathogenesis of preclinical and human multiple sclerosis: In silico and in vivo evidences. Journal of Neuroimmunology, 2018, 322, 46-56.	2.3	69

#	Article	IF	Citations
37	Exploring the biological functional mechanism of the HMGB1/TLR4/MD-2 complex by surface plasmon resonance. Molecular Medicine, 2018, 24, 21.	4.4	50
38	HMGB1 Causes Anemia of Inflammation By Modulating Erythropoietin Signal Transduction. Blood, 2018, 132, 628-628.	1.4	1
39	Î²â€Hydroxyâ€tetrahydroquinolines from Quinolines Using Chloroborane: Synthesis of the Peptidomimetic FISLEâ€412. Chemistry - A European Journal, 2017, 23, 10738-10743.	3.3	8
40	A structural investigation of FISLE-412, a peptidomimetic compound derived from saquinavir that targets lupus autoantibodies. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4725-4729.	2.2	6
41	The challenges of modulating the â€˜rest and digestâ€™ system: acetylcholine receptors as drug targets. Drug Discovery Today, 2017, 22, 97-104.	6.4	9
42	Activation of the cholinergic anti-inflammatory pathway by GTS-21 attenuates cisplatin-induced acute kidney injury in mice. PLoS ONE, 2017, 12, e0188797.	2.5	28
43	Cathepsin L Promotes Vascular Intimal Hyperplasia after Arterial Injury. Molecular Medicine, 2017, 23, 92-100.	4.4	29
44	The Multi-target Effects of CNI-1493: Convergence of Antiamylodogenic and Antiinflammatory Properties in Animal Models of Alzheimerâ€™s Disease. Molecular Medicine, 2016, 22, 776-788.	4.4	3
45	Emetine Di-HCl Attenuates Type 1 Diabetes Mellitus in Mice. Molecular Medicine, 2016, 22, 585-596.	4.4	5
46	C1q and HMGB1 reciprocally regulate human macrophage polarization. Blood, 2016, 128, 2218-2228.	1.4	130
47	Effects of novel muscarinic M3 receptor ligand C1213 in pulmonary arterial hypertension models. Physiological Reports, 2016, 4, e13069.	1.7	9
48	Amending HIV Drugs: A Novel Small-Molecule Approach To Target Lupus Anti-DNA Antibodies. Journal of Medicinal Chemistry, 2016, 59, 8859-8867.	6.4	13
49	Pomalidomide reverses Î³-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors. Blood, 2016, 127, 1481-1492.	1.4	75
50	MIF, a controversial cytokine: a review of structural features, challenges, and opportunities for drug development. Expert Opinion on Therapeutic Targets, 2016, 20, 1463-1475.	3.4	70
51	Identification of Iguratimod as an Inhibitor of Macrophage Migration Inhibitory Factor (MIF) with Steroid-sparing Potential. Journal of Biological Chemistry, 2016, 291, 26502-26514.	3.4	50
52	Pharmacological Inhibition of the Protein Kinase MRK/ZAK Radiosensitizes Medulloblastoma. Molecular Cancer Therapeutics, 2016, 15, 1799-1808.	4.1	13
53	Effects of NO-Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 306-315.	2.5	19
54	The Macrophage Inhibitor CNI-1493 Blocks Metastasis in a Mouse Model of Ewing Sarcoma through Inhibition of Extravasation. PLoS ONE, 2015, 10, e0145197.	2.5	15

#	Article	IF	Citations
55	The HIV Protease Inhibitor Saquinavir Inhibits HMGBl-Driven Inflammation by Targeting the Interaction of Cathepsin V with TLR4/MyD88. Molecular Medicine, 2015, 21, 749-757.	4.4	17
56	Rodent models of neuroinflammation for Alzheimerâ€™s disease. Journal of Neuroinflammation, 2015, 12, 74.	7.2	191
57	MD-2 is required for disulfide HMGB1â€“dependent TLR4 signaling. Journal of Experimental Medicine, 2015, 212, 5-14.	8.5	295
58	The cation channel Trpv2 is a new suppressor of arthritis severity, joint damage, and synovial fibroblast invasion. Clinical Immunology, 2015, 158, 183-192.	3.2	33
59	Cholinergic anti-inflammatory pathway activity in dialysis patients: a role for neuroimmunomodulation?. CKJ: Clinical Kidney Journal, 2015, 8, 599-605.	2.9	12
60	HMGB1-Driven Inflammation and Intimal Hyperplasia After Arterial Injury Involves Cell-Specific Actions Mediated by TLR4. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2579-2593.	2.4	62
61	Xanomeline suppresses excessive pro-inflammatory cytokine responses through neural signal-mediated pathways and improves survival in lethal inflammation. Brain, Behavior, and Immunity, 2015, 44, 19-27.	4.1	64
62	Pomalidomide Transcriptionally Reprograms Adult Erythroid Progenitors Independently of Ikaros Proteasomal Degradation. Blood, 2015, 126, 160-160.	1.4	1
63	A Novel Mechanism of B Cellâ€“Mediated Immune Suppression through CD73 Expression and Adenosine Production. Journal of Immunology, 2014, 193, 5904-5913.	0.8	113
64	Novel Arylazoarylmethane as Potential Inhibitor of Macrophage Migration Inhibitory Factor. Archiv Der Pharmazie, 2014, 347, 104-107.	4.1	3
65	Novel inhibitors of macrophage migration inhibitory factor prevent cytokine-induced beta cell death. European Journal of Pharmacology, 2014, 740, 683-689.	3.5	11
66	ISO-66, a novel inhibitor of macrophage migration inhibitory factor, shows efficacy in melanoma and colon cancer models. International Journal of Oncology, 2014, 45, 1457-1468.	3.3	25
67	Semapimod Sensitizes Glioblastoma Tumors to Ionizing Radiation by Targeting Microglia. PLoS ONE, 2014, 9, e95885.	2.5	11
68	Sequestering HMGB1 via DNA-Conjugated Beads Ameliorates Murine Colitis. PLoS ONE, 2014, 9, e103992.	2.5	24
69	Elaborate ligand-based modeling reveal new migration inhibitory factor inhibitors. Journal of Molecular Graphics and Modelling, 2013, 42, 104-114.	2.4	18
70	CNI-1493 Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in the Acute MPTP Mouse Model of Parkinson's Disease. Neurodegenerative Diseases, 2013, 12, 103-110.	1.4	11
71	Structural Basis and Targeting of the Interaction between Fibroblast Growth Factor-inducible 14 and Tumor Necrosis Factor-like Weak Inducer of Apoptosis. Journal of Biological Chemistry, 2013, 288, 32261-32276.	3.4	20
72	Identification of Pharmacological Modulators of HMGB1-Induced Inflammatory Response by Cell-Based Screening. PLoS ONE, 2013, 8, e65994.	2.5	31

#	Article	IF	Citations
73	Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL. Cell Cycle, 2012, 11, 1174-1182.	2.6	14
74	Redox Modification of Cysteine Residues Regulates the Cytokine Activity of High Mobility Group Box-1 (HMGB1). Molecular Medicine, 2012, 18, 250-259.	4.4	378
75	Therapeutic Potential of Nitric Oxide-Modified Drugs in Colon Cancer Cells. Molecular Pharmacology, 2012, 82, 700-710.	2.3	28
76	Neural Signaling in the Spleen Controls B-Cell Responses to Blood-Borne Antigen. Molecular Medicine, 2012, 18, 618-627.	4.4	62
77	C1q limits dendritic cell differentiation and activation by engaging LAIR-1. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3160-7.	7.1	149
78	Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells. Oncology Reports, 2012, 28, 682-688.	2.6	18
79	Macrophage Migration Inhibitory Factor Antagonist Blocks the Development of Endometriosis In Vivo. PLoS ONE, 2012, 7, e37264.	2.5	39
80	Macrophage Migration Inhibitory Factor Mediates Hypoxia-Induced Pulmonary Hypertension. Molecular Medicine, 2012, 18, 215-223.	4.4	63
81	Resveratrol mitigates lipopolysaccharideâ€•and AÎ²â€•mediated microglial inflammation by inhibiting the TLR4/NFâ€ÎºB/STAT signaling cascade. Journal of Neurochemistry, 2012, 120, 461-472.	3.9	363
82	Nicotinic Acetylcholine Receptor Agonists Attenuate Septic Acute Kidney Injury in Mice by Suppressing Inflammation and Proteasome Activity. PLoS ONE, 2012, 7, e35361.	2.5	60
83	MIF as a disease target: ISO-1 as a proof-of-concept therapeutic. Future Medicinal Chemistry, 2011, 3, 45-63.	2.3	87
84	In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle, 2011, 10, 492-499.	2.6	47
85	Influenza Virus Infection Aggravates Stroke Outcome. Stroke, 2011, 42, 783-791.	2.0	104
86	The Role of CNI-1493 in the Function of Primary Microglia with Respect to Amyloid-Î². Journal of Alzheimer's Disease, 2011, 26, 69-80.	2.6	25
87	The new and less toxic protease inhibitor saquinavirâ€“NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir. Antiviral Research, 2011, 91, 292-295.	4.1	9
88	Cytotoxic and immune-sensitizing properties of nitric oxide-modified saquinavir in iNOS-positive human melanoma cells. Journal of Cellular Physiology, 2011, 226, 1803-1812.	4.1	30
89	Thyroxine is a potential endogenous antagonist of macrophage migration inhibitory factor (MIF) activity. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 8224-8227.	7.1	41
90	Cardiopulmonary Arrest and Resuscitation Disrupts Cholinergic Anti-Inflammatory Processes: A Role for Cholinergic Î±7 Nicotinic Receptors. Journal of Neuroscience, 2011, 31, 3446-3452.	3.6	52

#	Article	IF	Citations
91	Naturally Occurring Autoantibodies against Î²-Amyloid: Investigating Their Role in Transgenic Animal andIn VitroModels of Alzheimer's Disease. Journal of Neuroscience, 2011, 31, 5847-5854.	3.6	111
92	Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 10255-10259.	7.1	53
93	Inhibition of Macrophage Migration Inhibitory Factor Reduces Endometriotic Implant Size in Mice with Experimentally Induced Disease. Journal of Endometriosis, 2011, 3, 135-142.	1.0	9
94	Inhibition of macrophage migration inhibitory factor reduces endometriotic implant size in mice with experimentally induced disease. Journal of Endometriosis, 2011, 3, 135-142.	1.0	10
95	Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO. Free Radical Biology and Medicine, 2010, 48, 1090-1099.	2.9	10
96	ISO-1, a Macrophage Migration Inhibitory Factor Antagonist, Inhibits Airway Remodeling in a Murine Model of Chronic Asthma. Molecular Medicine, 2010, 16, 400-408.	4.4	49
97	The Role of Macrophage Migration Inhibitory Factor in Alzheimerâ€™s Disease. Molecular Medicine, 2010, 16, 116-121.	4.4	80
98	A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 11942-11947.	7.1	705
99	Macrophage Migration Inhibitory Factor Elicits an Angiogenic Phenotype in Human Ectopic Endometrial Cells and Triggers the Production of Major Angiogenic Factors via CD44, CD74, and MAPK Signaling Pathways. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E403-E412.	3.6	72
100	Intrathecal injection of an alpha seven nicotinic acetylcholine receptor agonist attenuates gp120-induced mechanical allodynia and spinal pro-inflammatory cytokine profiles in rats. Brain, Behavior, and Immunity, 2010, 24, 959-967.	4.1	44
101	Anticancer Effects of the Nitric Oxide-Modified Saquinavir Derivative Saquinavir-NO against Multidrug-Resistant Cancer Cells. Neoplasia, 2010, 12, 1023-IN17.	5.3	51
102	The Selective Î±7 Agonist GTS-21 Attenuates Cytokine Production in Human Whole Blood and Human Monocytes Activated by Ligands for TLR2, TLR3, TLR4, TLR9, and RAGE. Molecular Medicine, 2009, 15, 195-202.	4.4	175
103	Macrophage Migration Inhibitory Factor Promotes Colorectal Cancer. Molecular Medicine, 2009, 15, 1-10.	4.4	96
104	The antitumor properties of a nontoxic, nitric oxideâ€“modified version of saquinavir are independent of Akt. Molecular Cancer Therapeutics, 2009, 8, 1169-1178.	4.1	38
105	Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain, Behavior, and Immunity, 2009, 23, 41-45.	4.1	378
106	Platinum and Palladium Complexes Bearing New (1R,2R)-(-)-1,2-Diaminocyclohexane (DACH)-Based Nitrogen Ligands: Evaluation of the Complexes Against L1210 Leukemia. Zeitschrift Fur Anorganische Und Allgemeine Chemie, 2008, 634, 2655-2658.	1.2	10
107	Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. Journal of Cellular Physiology, 2008, 215, 665-675.	4.1	76
108	Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acidâ€“nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells. Nitric Oxide - Biology and Chemistry, 2008, 19, 177-183.	2.7	26

#	Article	IF	Citations
109	Macrophage migration inhibitory factor induces cardiomyocyte apoptosis. Biochemical and Biophysical Research Communications, 2008, 371, 298-303.	2.1	25
110	Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo. Molecular Cancer Therapeutics, 2008, 7, 510-520.	4.1	68
111	CNI-1493 inhibits AÎ² production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease. Journal of Experimental Medicine, 2008, 205, 1593-1599.	8.5	21
112	Modulation of TNF Release by Choline Requires Î±7 Subunit Nicotinic Acetylcholine Receptor-Mediated Signaling. Molecular Medicine, 2008, 14, 567-574.	4.4	288
113	Alternative Chemical Modifications Reverse the Binding Orientation of a Pharmacophore Scaffold in the Active Site of Macrophage Migration Inhibitory Factor. Journal of Biological Chemistry, 2007, 282, 23089-23095.	3.4	47
114	Regulation of Human Lung Adenocarcinoma Cell Migration and Invasion by Macrophage Migration Inhibitory Factor. Journal of Biological Chemistry, 2007, 282, 29910-29918.	3.4	97
115	Lung-Derived Macrophage Migration Inhibitory Factor in Sepsis Induces Cardio-Circulatory Depression. Surgical Infections, 2007, 8, 29-40.	1.4	20
116	A Potent Immunomodulatory Compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxasole Acetic Acid, Prevents Spontaneous and Accelerated Forms of Autoimmune Diabetes in NOD Mice and Inhibits the Immunoinflammatory Diabetes Induced by Multiple Low Doses of Streptozotocin in CBA/H Mice. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 1038-1049.	2.5	32
117	Selective Î±7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis*. Critical Care Medicine, 2007, 35, 1139-1144.	0.9	352
118	Phenolic Hydrazones Are Potent Inhibitors of Macrophage Migration Inhibitory Factor Proinflammatory Activity and Survival Improving Agents in Sepsis. Journal of Medicinal Chemistry, 2007, 50, 1993-1997.	6.4	54
119	Nicotine Inhibits Cytokine Production by Placenta Cells via NFÎºB: Potential Role in Pregnancy-Induced Hypertension. Molecular Medicine, 2007, 13, 576-583.	4.4	53
120	Imbalance in Seminal Fluid MIF Indicates Male Infertility. Molecular Medicine, 2007, 13, 199-202.	4.4	19
121	Critical modifications of the ISO-1 scaffold improve its potent inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3376-3379.	2.2	44
122	Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5219-5223.	7.1	295
123	Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. Journal of Experimental Medicine, 2005, 201, 1113-1123.	8.5	444
124	MACROPHAGE MIGRATION INHIBITORY FACTOR WITHIN THE ALVEOLAR SPACES INDUCES CHANGES IN THE HEART DURING LATE EXPERIMENTAL SEPSIS. Shock, 2005, 24, 556-563.	2.1	25
125	ISO-1 Binding to the Tautomerase Active Site of MIF Inhibits Its Pro-inflammatory Activity and Increases Survival in Severe Sepsis. Journal of Biological Chemistry, 2005, 280, 36541-36544.	3.4	264
126	Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nature Medicine, 2004, 10, 1216-1221.	30.7	1,624

#	Article	IF	Citations
127	Targeting Malaria with Polyamines. Bioconjugate Chemistry, 2004, 15, 1161-1165.	3.6	6
128	Nicotinic acetylcholine receptor Î±7 subunit is an essential regulator of inflammation. Nature, 2003, 421, 384-388.	27.8	3,346
129	The Tautomerase Active Site of Macrophage Migration Inhibitory Factor Is a Potential Target for Discovery of Novel Anti-inflammatory Agents. Journal of Biological Chemistry, 2002, 277, 24976-24982.	3.4	250
130	Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 144-149.	7.1	154
131	Neuroprotection in cerebral ischemia by neutralization of 3-aminopropanal. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 5579-5584.	7.1	75
132	Release of Macrophage Migration Inhibitory Factor and CXCL8/Interleukin-8 from Lung Epithelial Cells Rendered Necrotic by Influenza A Virus Infection. Journal of Virology, 2002, 76, 9298-9306.	3.4	89
133	Inhibition of MIF Bioactivity by Rational Design of Pharmacological Inhibitors of MIF Tautomerase Activity. Journal of Medicinal Chemistry, 2002, 45, 2410-2416.	6.4	115
134	Inhibition of HIV-1 nuclear import via schiff base formation with arylene bis(methylketone) compounds. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 3117-3119.	2.2	15
135	Hydroformylation of cyclopentenes, novel strategy for total synthesis of carba- d -fructofuranose. Tetrahedron Letters, 2002, 43, 1793-1795.	1.4	17
136	Hydroformylation of glycals using a rhodium(I)(acac)(CO) 2 catalyst. Tetrahedron Letters, 2002, 43, 8607-8609.	1.4	6
137	An enantioselective approach to trehazolin: a concise and efficient synthesis of the aminocyclopentitol core. Tetrahedron Letters, 2001, 42, 1471-1473.	1.4	15
138	Synthesis and Properties of a-Thiagra. A Substituted 5-(2-Thienyl)pyrazolo[4,3-d]pyrimidin-7-one Bioisostere of ViagraÂ®. Heterocycles, 2000, 53, 2643.	0.7	7
139	The polyhydroxy cyclopentene, a total synthesis of (-)-pentenomycin. Tetrahedron Letters, 2000, 41, 4291-4293.	1.4	30
140	Studies directed toward the synthesis of carba-d-arabinofuranose. Tetrahedron Letters, 2000, 41, 7801-7803.	1.4	32
141	Structure of a Synthetic Glucose Derived Advanced Glycation End Product That Is Immunologically Cross-Reactive with Its Naturally Occurring Counterparts. Bioconjugate Chemistry, 2000, 11, 39-45.	3.6	28
142	Total Synthesis of Carba-d-fructofuranose via a Novel Metathesis Reaction. Organic Letters, 1999, 1, 1463-1465.	4.6	35
143	Detoxification of Methylglyoxal by the Nucleophilic Bidentate, Phenylacylthiazolium Bromide. Chemical Research in Toxicology, 1999, 12, 617-622.	3.3	15
144	[11] Advanced glycation end products: Detection and reversal. Methods in Enzymology, 1999, 309, 152-172.	1.0	32

#	Article	IF	Citations
145	A stereospecific synthesis of tetra-substituted chiral piperazines. Tetrahedron Letters, 1998, 39, 7703-7704.	1.4	9
146	A arylnaphthalene lignan from Haplophyllum buxbaumii. Phytochemistry, 1998, 49, 1779-1781.	2.9	13
147	Identification of N2-(1-carboxymethyl)guanine (CMG) as a guanine advanced glycation end product. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 2109-2110.	2.2	7
148	Cerebral Ischemia Enhances Polyamine Oxidation: Identification of Enzymatically Formed 3-Aminopropanal as an Endogenous Mediator of Neuronal and Glial Cell Death. Journal of Experimental Medicine, 1998, 188, 327-340.	8.5	110
149	Efficient Scavenging of Fatty Acid Oxidation Products by Aminoguanidine. Chemical Research in Toxicology, 1997, 10, 875-879.	3.3	38
150	An expeditious methodology for the incorporation of unsaturated systems into carbohydrates via an enol triflate. Tetrahedron Letters, 1997, 38, 7303-7306.	1.4	4
151	Pyridinium Ions Adjacent to Oxirane Rings: Useful Intermediates for the Stereospecific Synthesis ofÎ²-Hydroxy Ketones. Angewandte Chemie International Edition in English, 1996, 35, 523-524.	4.4	14
152	Novel modifications of NÎ±-boc-arginine and NÎ±-CBZ-lysine by methylglyoxal. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 1577-1578.	2.2	20
153	4-O-TfO-2,3-anhydro-Î²-L-ribopyranosides as chiron: A formal synthesis of canadensolide. Tetrahedron Letters, 1996, 37, 8641-8642.	1.4	21
154	Hydroxyalkenal Formation Induced by Advanced Glycosylation of Low Density Lipoprotein. Journal of Biological Chemistry, 1996, 271, 2892-2896.	3.4	28
155	Circular dichroism of carbohydrate-molybdate complexes. Studies in Natural Products Chemistry, 1995, 15, 423-438.	1.8	2
156	Model studies of the maillard reaction of Arg-Lys with D-ribose. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 2929-2930.	2.2	9
157	NÎµ-carboxymethyllysine formation by direct addition of glyoxal to lysine during the Maillard reaction. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 2161-2162.	2.2	25
158	Synthesis of Chiral Î²-oxy-Î³-lactones on Sugar Templates: Influence of the Substituents Around C-6 on the Conformation of the Pyranose Ring. Natural Product Research, 1994, 4, 73-78.	0.4	0
159	Synthesis of polyfunctionalized bis-annulated pyranosides: Useful intermediates for triquinane synthesis. Tetrahedron Letters, 1994, 35, 8581-8582.	1.4	25
160	Enol Triflate Pyranoses, Versatile Reagents for the Formation of Conjugated Systems on Pyranoses. Angewandte Chemie International Edition in English, 1994, 33, 1499-1501.	4.4	17
161	Chiral Î´-lactones via Pyranose-annulation. Natural Product Research, 1994, 4, 273-277.	0.4	3
162	Stereoselective synthesis of Î²-oxy- and Î±-methylene-Î³-butyrolactones on pyranose templates. Tetrahedron, 1993, 49, 9295-9306.	1.9	26

#	Article	IF	Citations
163	Expeditious entries to chiral furanoids via pyranose annulation. Tetrahedron Letters, 1993, 34, 7717-7720.	1.4	14
164	Two arylnaphthalene lignans from Haplophyllum buxbaumii. Phytochemistry, 1990, 29, 2659-2661.	2.9	6
165	Chemical Constituents of the Flora of Jordan, Part V-B. Three New Arylnaphthalene Lignan Glucosides from Haplophyllum buxbaumii. Journal of Natural Products, 1990, 53, 1152-1161.	3.0	31